

Innolight (300308 CH)

4Q20 in-line; 400G upgrade and hyperscale capex recovery to drive growth in 2021

Innolight announced FY20E preliminary net profit of RMB780mn-905mn, up 52%-76% YoY, with mid-point of RMB843mn (+64% YoY) largely in-line with our/consensus estimates of RMB870/863mn. By 4Q20, we estimate revenue/net profit of RMB1,909mn/252mn, up 30%/62% YoY. The strong result was driven by robust data traffic and increasing capex from global/china hyperscalers. We slightly adjusted our estimates for 4Q20 results, and revised our TP to RMB 72.66 is based on same 42x FY21E P/E (2-year historical average). Innolight now trades at lower end of its historical valuation band, and we believe concerns over hyperscale capex slowdown in 2021 is overdone. Reiterate BUY. Upcoming catalysts include stronger cloud capex and 5G deployment.

- FY20 NP largely in-line; Solid growth in Q4.** Innolight reported FY20 preliminary net profit of RMB780-905mn (+52%-76% YoY), largely in-line with our/consensus estimates, mainly driven by global hyperscale capex from major cloud companies (e.g. Google, Amazon, Facebook, Microsoft) and rapid 400G upgrade. For 4Q20, we estimate revenue/net profit grew 25%/62% YoY (vs +57%/56% YoY in 3Q20), given slower China 5G deployment but improving margins due to better product mix and yield of 400G products.
- Expect strong demand pick-up in 2Q/3Q21E.** Looking into FY21E, we expect weaker 1Q21E on seasonality and sequential demand pick-up into 2Q/3Q21E, driven by datacom demand ramp from overseas clients. As the global largest supplier of 100G/200G/400G optical modules and increasing presence in telecom market, we expect Innolight to become the major beneficiary of secular data growth and 400G datacom upgrade cycle. We expect Innolight to deliver 29%/37% revenue/NP CAGR during FY20-22E.
- Maintain BUY with new TP of RMB72.66.** We reiterate BUY and adjusted our target price to RMB72.66 based on same 41.9x FY21E P/E, after slight revision of our forecasts. Trading at 29.7x FY21E P/E (1-sd below 2-year avg.), we think the stock is attractive, compared to 39% EPS FY20-22E CAGR. Potential risks include weaker capex from global cloud companies, slower deployment of 5G infrastructure and higher ASP pressure.

Earnings Summary

(YE 31 Dec)	FY18A	FY19A	FY20E	FY21E	FY22E
Revenue (RMB mn)	5,156	4,758	7,114	9,561	11,784
YoY growth (%)	118.8	(7.7)	49.5	34.4	23.2
Net profit (RMB mn)	623	513	851	1,235	1,588
EPS (RMB)	1.36	0.73	1.19	1.73	2.23
YoY growth (%)	172%	-46%	64%	45%	29%
PE (x)	37.8	70.4	43.0	29.7	23.1
PB (x)	5.1	5.3	4.6	4.0	3.5
Yield (%)	0.2	0.2	0.2	0.3	0.4
ROE (%)	12.4	6.2	9.4	13.6	15.0
Net gearing (%)	Net cash	2.3	15.1	7.9	14.3

Source: Company data, CMBIS estimates

BUY (Maintain)

Target Price	RMB 72.66
(Previous TP)	RMB 73.45)
Up/Downside	+41.5%
Current Price	RMB 51.37

China Technology Sector

Alex Ng
 (852) 3900 0881
 alexng@cmbi.com.hk

Lily Yang
 (852) 3916 3716
 lilyyang@cmbi.com.hk

Stock Data

Mkt. Cap. (RMB mn)	36,635
Avg. 3mths t/o (RMB mn)	362
52W High/Low (RMB)	73.45/46.66
Total Issued Shares (mn)	713.2

Source: Bloomberg

Shareholding Structure

Zhongji Investment	18.17%
HKSC	8.48%
SZ Yixingfu Ent Mgmt	7.04%


Source: Bloomberg

Share Performance

	Absolute	Relative
1-mth	6.9%	0.4%
3-mth	8.1%	-0.7%
6-mth	-3.3%	-14.3%

Source: Bloomberg

12-mth Price Performance



Source: Bloomberg

**Auditor: PricewaterhouseCoopers
 Zhong Tian**

Recent Reports:

China 5G Technology - Picking structural winners amid uncertainties; Initiate at Outperform – 18 Dec 2020

4Q20 Review

Figure 1: 4Q20 results review

RMB mn	3Q19	4Q19	1Q20	2Q20	3Q20	4Q20E	QoQ	YoY
Revenue	1,249	1,474	1,326	1,919	1,960	1,909	-2.6%	29.5%
Gross Profit	350	361	331	490	477	474	-0.7%	31.5%
Operating Profit	157	188	173	257	269	298	11.0%	59.1%
Net profit	151	156	154	211	235	251	7.1%	61.6%
EPS (RMB)	0.23	0.23	0.22	0.30	0.33	0.35	7.1%	54.3%
Gross Margin	28.1%	24.5%	24.9%	25.5%	24.4%	24.8%	0.5 ppt	0.4 ppt
Operating Margin	12.6%	12.7%	13.1%	13.4%	13.7%	15.6%	1.9 ppt	2.9 ppt
Net Margin	12.1%	10.6%	11.6%	11.0%	12.0%	13.2%	1.2 ppt	2.6 ppt

Source: Company data, Bloomberg, CMBIS estimates

Figure 2: P&L forecasts

RMB mn	FY18A	FY19A	1Q20	2Q20	3Q20	4Q20E	FY20E	FY21E	FY22E
Revenue	5,156	4,758	1,326	1,919	1,960	1,909	7,114	9,561	11,784
...YoY	119%	-8%	51%	65%	57%	30%	50%	34%	23%
Cost of sales	(3,750)	(3,468)	(995)	(1,429)	(1,483)	(1,435)	(5,341)	(7,140)	(8,729)
Gross profit	1,406	1,290	331	490	477	474	1,772	2,421	3,055
GPM (%)	27.3%	27.1%	24.9%	25.5%	24.4%	24.8%	24.9%	25.3%	25.9%
...YoY	123%	-8%	34%	47%	36%	31%	37%	37%	26%
SG&A	(314)	(329)	(87)	(98)	(141)	(173)	(498)	(593)	(731)
...% of rev	-6.1%	-6.9%	-6.5%	-5.1%	-7.2%	-9.1%	-7.0%	-6.2%	-6.2%
R&D	(309)	(362)	(88)	(88)	(117)	(113)	(405)	(545)	(672)
...% of rev	-6.0%	-7.6%	-6.6%	-4.6%	-5.9%	-5.9%	-5.7%	-5.7%	-5.7%
Operating profit	682	576	173	257	269	298	998	1,424	1,830
OPM (%)	13.2%	12.1%	13.1%	13.4%	13.7%	15.6%	14.0%	14.9%	15.5%
...YoY	231%	-15%	48%	123%	72%	59%	73%	43%	29%
Net profit	623	513	154	211	235	251	851	1,235	1,588
NPM (%)	12.1%	10.8%	11.6%	11.0%	12.0%	13.2%	12.0%	12.9%	13.5%
...YoY	286%	-18%	54%	96%	56%	62%	239%	45%	29%

Source: Company data, CMBIS estimates

Forecasts revision

Figure 3: CMBIS estimate revisions

RMB mn	New			Old			Diff (%)		
	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E
Revenue	7,114	9,561	11,784	7,246	9,746	11,998	-2%	-2%	-2%
Gross Profit	1,772	2,421	3,055	1,866	2,559	3,265	-5%	-5%	-6%
Operating Profit	998	1,424	1,830	999	1,432	1,855	0%	-1%	-1%
Net profit	851	1,235	1,588	870	1,249	1,619	-2%	-1%	-2%
EPS (RMB)	1.19	1.73	2.23	1.22	1.75	2.27	-2%	-1%	-2%
Gross Margin	24.9%	25.3%	25.9%	25.8%	26.3%	27.2%	-0.8 ppt	-0.9 ppt	-1.3 ppt
Operating Margin	14.0%	14.9%	15.5%	13.8%	14.7%	15.5%	0.2 ppt	0.2 ppt	0.1 ppt
Net Margin	12.0%	12.9%	13.5%	12.0%	12.8%	13.5%	0 ppt	0.1 ppt	0 ppt

Source: Company data, CMBIS estimates

Figure 4: CMBIS estimates vs consensus

RMB mn	CMBIS			Consensus			Diff (%)		
	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E
Revenue	7,114	9,561	11,784	7,060	9,052	11,068	1%	6%	6%
Gross Profit	1,772	2,421	3,055	1,833	2,373	2,926	-3%	2%	4%
Operating Profit	998	1,424	1,830	960	1,341	1,715	4%	6%	7%
Net profit	851	1,235	1,588	835	1,133	1,446	2%	9%	10%
EPS (RMB)	1.19	1.73	2.23	1.18	1.60	2.06	1%	8%	8%
Gross Margin	24.9%	25.3%	25.9%	26.0%	26.2%	26.4%	-1 ppt	-0.9 ppt	-0.5 ppt
Operating Margin	14.0%	14.9%	15.5%	13.6%	14.8%	15.5%	0.4 ppt	0.1 ppt	0 ppt
Net Margin	12.0%	12.9%	13.5%	11.8%	12.5%	13.1%	0.1 ppt	0.4 ppt	0.4 ppt

Source: Company data, CMBIS estimates

Figure 5: Revenue breakdown

RMB mn	FY18A	FY19A	FY20E	FY21E	FY22E
10G/40G modules	1,249	1,030	1,121	1,643	1,563
...YoY	36%	-18%	-15%	-2%	-12%
25G/100G/400G modules	3,749	3,601	5,828	7,713	9,974
...YoY	190%	-4%	62%	32%	29%
High-end equipment	159	127	165	206	247
...YoY	6%	-20%	30%	25%	20%
Total	5,156	4,758	7,114	9,561	11,784
...YoY	119%	-8%	50%	34%	23%
Gross Margin					
10G/40G modules	24.4%	29.2%	23.9%	22.8%	23.2%
25G/100G/400G modules	28.2%	26.7%	25.3%	26.0%	26.5%
High-end equipment	29.4%	20.5%	20.0%	20.0%	20.0%
Total	27.3%	27.1%	24.9%	25.3%	25.9%

Source: Company data, CMBIS estimates

Valuation

Maintain BUY with new TP RMB72.66 (41.5% upside)


We derived our new 12m TP of RMB72.66 based on same 41.9x FY20E P/E, in line with its 2-year historical average. We believe this is justified as Innolight is the industry leader in the fast growing optical module market. Upcoming catalysts include increasing demand of 200G/400G/800G and share gain in China telecom market. Potential risks include weaker capex from cloud giants, slower deployment of 5G infrastructure and ASP pressure.

Figure 6: Peers' valuation

Company	Ticker	Rating	Mkt Cap		TP	Up/Down	P/E (x)		P/B (x)		ROE (%)	
			US\$(mn)	(LC)			(LC)	-side	FY20E	FY21E	FY20E	FY21E
Innolight	300308 CH	Buy	5,747	51.80	72.66	42%	43.0	29.7	4.6	4.0	9.4	13.6
Accelink Tech	002281 CH	NR	2,810	25.88	NA	NA	35.6	29.7	3.6	3.2	10.1	10.8
Eoptolink Tech	300502 CH	NR	3,082	54.69	NA	NA	39.2	28.8	8.6	6.9	25.4	26.4
HG Genuine	000988 CH	NR	3,565	22.79	NA	NA	36.9	32.9	3.4	3.0	10.1	10.9
FIT Hon Teng	6088 HK	NR	2,943	3.31	NA	NA	18.6	13.8	1.3	1.2	7.4	9.2
Lumentum	LITE US	NR	7,102	93.80	NA	NA	18.5	15.0	4.1	3.6	24.0	25.3
Finisar	IIVI US	NR	8,720	84.07	NA	NA	38.5	24.8	3.8	3.0	11.8	15.3
Sumitomo	8053 JT	NR	16,576	1387.00	NA	NA	8.8	-	0.6	0.7	8.7	(4.1)
NeoPhotonics	NPTN US	NR	559	11.14	NA	NA	40.5	-	3.2	3.3	8.9	(4.3)
Csico	CSCO US	NR	188,172	44.58	NA	NA	14.2	14.1	5.2	4.6	37.8	33.2
Average							29.3	23.5	3.8	3.4	15.5	13.7


Source: Bloomberg, CMBIS estimates

Figure 7: 12M forward P/E band



Source: Company data, CMBIS estimates

Figure 8: 12M forward P/B band



Source: Company data, CMBIS estimates

Financial Summary

Income statement

YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Revenue	5,156	4,758	7,114	9,561	11,784
Cost of sales	3,750	3,468	5,341	7,140	8,729
Gross profit	1,406	1,290	1,772	2,421	3,055
Tax and surcharges	10	17	18	19	24
Selling exp	60	55	114	143	177
Admin exp (excl. R&D)	253	275	384	449	554
R&D exp	309	362	405	545	672
Finance costs	79	17	49	74	89
Other operating exp.	22	5	(178)	(214)	(267)
Operating profit	682	576	998	1,424	1,830
Other non-oper exp.	13	0	(5)		
Pre-tax profit	695	577	993	1,424	1,830
Income tax expense	72	63	134	178	229
Minority interests			8	11	14
Net profit	623	513	851	1,235	1,588
Adj. net profit	590	430	745	1,235	1,588

Cash flow summary

YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Net profit	623	513	859	1,246	1,602
Depreciation/amortization	201	241	386	518	668
Change in working capital	(441)	(360)	(1,841)	134	(1,944)
Others	277	175	120	141	176
Net cash from operating	660	569	(477)	2,039	502
Capex	(608)	(759)	(1,132)	(1,177)	(1,167)
Other	(65)	(1,180)	269	(62)	(93)
Net cash from investing	(673)	(1,939)	(862)	(1,238)	(1,260)
Share issuance	52	1,524	(0)	0	0
Net borrowing	151	159	1,353	322	1,347
Other	(66)	(126)	104	(162)	(236)
Net cash from financing	137	1,557	1,458	160	1,111
Net change in cash	139	195	101	961	353
Cash at beginning of the year	902	1,041	1,236	1,337	2,298
Exchange difference	15	8	(17)	0	0
Cash at the end of year	1,041	1,236	1,370	2,331	2,684

Balance sheet

YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Current assets	4,158	5,991	8,632	10,025	12,609
Cash & equivalents	1,041	1,236	1,370	2,331	2,684
Account receivables	840	1,133	2,109	2,092	2,960
Inventory	2,119	2,504	4,023	4,344	5,485
Prepayment	55	65	31	31	31
Other current assets	103	1,054	1,099	1,226	1,449
Non-current assets	3,922	4,500	5,425	6,084	6,583
PPE	1,497	1,950	2,794	3,415	3,928
Goodwill	1,717	1,717	1,915	1,915	1,915
Intangible assets	384	311	398	573	776
Other non-current assets	325	522	319	182	-35
Total assets	8,080	10,491	14,058	16,109	19,192
Current liabilities	2,868	2,826	4,630	5,380	6,446
ST borrowings	390	933	1,684	1,877	2,686
Account payables	802	1,259	1,552	2,109	2,367
Other current liabilities	1,676	634	1,393	1,393	1,393
Non-current liabilities	436	739	1,494	1,623	2,162
LT borrowings	270	466	1,101	1,230	1,769
Deferred tax liability	69	109	164	164	164
Other non-current liabilities	98	164	229	229	229
Total liabilities	3,304	3,565	6,124	7,003	8,608
Share capital	475	713	713	713	713
Reserve	4,301	6,213	7,116	8,276	9,741
Minority interest	0	0	105	116	130
Total equity	4,776	6,926	7,934	9,106	10,584
Total liabilities and equity	8,080	10,491	14,058	16,109	19,192

Key ratios

YE 31 Dec	FY18A	FY19A	FY20E	FY21E	FY22E
Revenue mix					
10G/40G modules	25	22	13	9	7
25G/100G/400G modules	75	78	84	82	86
High-end equipment	3	3	2	2	2
Growth (%)					
Revenue	118.8	(7.7)	49.5	34.4	23.2
Gross profit	122.7	(8.3)	37.4	36.6	26.2
Operating profit	231.2	(15.5)	73.1	42.7	28.5
Adj. net profit	122.9	(27.2)	73.5	65.8	28.5
Profit & loss ratio (%)					
Gross margin	27.3	27.1	24.9	25.3	25.9
Operating margin	13.2	12.1	14.0	14.9	15.5
Net profit margin	12.1	10.8	12.0	12.9	13.5
Balance sheet ratio					
Gear ratio	Net cash	2.3	15.1	7.9	14.3
Current ratio (x)	1.5	2.1	1.9	1.9	2.0
Receivable turnover days	66	76	84	81	79
Inventory turnover days	151	185	174	166	159
Payable turnover days	120	108	96	94	94
Profitability (%)					
ROE	12.4	6.2	9.4	13.6	15.0
ROA	7.3	4.1	5.3	7.7	8.3
Per share data (RMB)					
EPS	1.36	0.73	1.19	1.73	2.23
DPS	0.12	0.08	0.10	0.17	0.22
BVPS	10.05	9.70	10.98	12.61	14.66

Source: Company data, CMBIS estimates

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIS Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIS

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.